• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    11/21/25 4:01:39 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care
    Get the next $PDEX alert in real time by email
    Current Report
    false 0000788920 0000788920 2025-11-20 2025-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): November 20, 2025

     

    PRO-DEX, INC.

    (Exact name of registrant as specified in charter)

     

    Colorado 0-14942 84-1261240
    (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)

     

    2361 McGaw Avenue

    Irvine, California 92614

    (Address of principal executive offices, zip code)

     

    (949) 769-3200

    (Registrant’s telephone number including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Exchange Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, no par value PDEX NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  ☐  

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     

     

     
     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Grant of Restricted Shares Awards

     

    On November 20, 2025, the Compensation Committee of the Board of Directors of Pro-Dex, Inc. (the “Company”) approved the grant of restricted common shares under the Company’s 2016 Equity Incentive Plan to the Company’s non-employee directors and to select employees, including 1,000 restricted shares granted to Alisha K. Charlton, the Company’s Chief Financial Officer, vesting ratably over five years.

     

    The restricted shares were granted pursuant to Restricted Shares Award Agreements (the “Award Agreements”), which contain terms and provisions customary for awards of this type, including that, in most instances, the employee must continue to be employed by the Company as of the applicable vesting date. A copy of the form of Award Agreement was attached as Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 25, 2024. The foregoing description of the Award Agreements is qualified in its entirety by reference to the complete text of the form of Award Agreement.

     

    Compensation of Chief Executive Officer

     

    On November 20, 2025, the Compensation Committee of the Board of Directors of Company approved a discretionary cash bonus to Richard L. Van Kirk, the Company’s Chief Executive Officer, of $30,830, which was calculated as the value of 1,000 shares of our common stock based on the closing sales price on the Nasdaq Capital Market on November 20, 2025. The bonus will be paid in cash in the next bi-weekly pay period with a pay date of November 26, 2025.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    On November 20, 2025, the Company held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on three proposals and two advisory votes set forth below. The proposals and advisory votes are described in detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on October 7, 2025 (the “Proxy Statement”).

     

      1. To elect Raymond E. Cabillot, Angelita R. Domingo, William J. Farrell III, David C. Hovda, Katrina M.K. Philp, Nicholas J. Swenson and Richard L. Van Kirk (the “Candidates”) to serve as members of the board of directors (“Board”) of the Company until their successors are duly elected and qualified.

     

    Candidate   Votes For   Withheld   Broker Non-Votes
    Raymond E. Cabillot     1,910,955       200,822       587,016  
    Angelita R. Domingo     2,103,305       8,472       587,016  
    William J. Farrell III     2,102,679       9,098       587,016  
    David C. Hovda     1,929,218       182,559       587,016  
    Katrina M.K. Philp     1,942,445       169,332       587,016  
    Nicholas J. Swenson     1,893,823       217,954       587,016  
    Richard L. Van Kirk     2,103,541       8,236       587,016  

     

    On the basis of the foregoing votes, each of the Candidates was elected.

     

     

     
     

     

     

      2. To ratify the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026.

     

    For   Against   Abstain   Broker Non-Votes
      2,692,619       4,489       1,685       —    
                                 

     

    On the basis of the foregoing votes, the proposal was ratified.

     

      3. To cast a non-binding advisory vote with regard to the compensation of the Company’s Named Executive Officers (as defined in the Proxy Statement) as set forth in the Proxy Statement.

     

    For   Against   Abstain   Broker Non-Votes
      2,064,143       19,916       27,718       587,016  
                                 

     

    On the basis of the foregoing votes, the shareholders approved, on a non-binding advisory basis, the compensation of the Named Executive Officers.

     

      4. To cast a non-binding advisory vote with regard to the frequency of future advisory votes on compensation of the Company’s Named Executive Officers.

     

    One Year   Two Years   Three  Years   Abstain
      2,038,224       4,565       45,377       23,611  
                                 

     

    On the basis of the foregoing votes, the shareholders approved, on a non-binding advisory basis, a one-year frequency on the advisory vote of the compensation of the Named Executive Officers.

     

      5. To amend the Company’s 2016 Equity Incentive Compensation Plan in order to extend its term for an additional ten years as set forth in the Proxy Statement.

     

    For   Against   Abstain   Broker Non-Votes
      1,942,832       162,366       6,579       587,016  
                                 

     

    On the basis of the foregoing votes, the proposal was approved.

      

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit Number Description
    104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

     

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 21, 2025 Pro-Dex, Inc.
       
         
      By: /s/ Alisha K. Charlton
        Alisha K. Charlton
        Chief Financial Officer

     

     

     

     
    Get the next $PDEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PDEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PDEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Philp Katrina Marie Kramer was granted 3,100 shares, increasing direct ownership by 45% to 2,900 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/24/25 4:00:02 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Van Kirk Richard Lee Jr covered exercise/tax liability with 72 shares, decreasing direct ownership by 0.07% to 99,707 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/21/25 6:46:37 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Director Swenson Nicholas John was granted 1,000 shares, increasing direct ownership by 1% to 97,613 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/21/25 6:45:52 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

    IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

    10/31/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Third Quarter And Nine-Month Results

    IRVINE, CA / ACCESSWIRE / May 2, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2024 with the Securities and Exchange Commission today.Quarter Ended March 31, 2024Net sales for the three months ended March 31, 2024, increased $1.2 million, or 9%, to $14.3 million from $13.1 million for the three months ended March 31, 2023, due primarily to an increase in medical device product revenue of $2.8 million offset by a decrease in non-recurring engineering and repair revenue of $736,000 and $635,000 respectively.Gross profit for

    5/2/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    SEC Filings

    View All

    Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    12/19/25 4:00:23 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    11/21/25 4:01:39 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    10/30/25 4:05:26 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Financials

    Live finance-specific insights

    View All

    PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

    IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

    10/31/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 First Quarter Results

    IRVINE, CA / ACCESSWIRE / November 2, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 first quarter ended September 30, 2023. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2024 with the Securities and Exchange Commission today.Net sales for the three months ended September 30, 2023, increased $851,000, or 8%, to $11.9 million from $11.1 million for the three months ended September 30, 2022. The increase is driven primarily by $1.8 million in increased repairs of the surgical handpiece we sell to our largest customer offset primarily by a decrease of $0.7 million in sales of our NRE & proto-type offerings

    11/2/23 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Pro-Dex Inc.

    SC 13D - PRO DEX INC (0000788920) (Filed by)

    10/17/23 5:00:05 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed

    SC 13D/A - PRO DEX INC (0000788920) (Subject)

    2/22/21 4:47:58 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care